Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
Featured trial
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

cell transplantation
myelofibrosis
  • 0 views
  • 24 Oct, 2022
  • 21 locations
Featured trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

myelodysplastic syndromes
multiple myeloma
chronic myelomonocytic leukaemia
hydroxyurea
bortezomib
  • 1 views
  • 21 Oct, 2022
  • 12 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536) …

vasectomy
erythropoietin
cancer
epoetin alfa
  • 16800 views
  • 22 Aug, 2022
  • 7 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

vasectomy
erythropoietin
cancer
epoetin alfa
  • 54541 views
  • 22 Aug, 2022
  • 9 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
  • 23120 views
  • 22 Aug, 2022
  • 10 locations
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may …

  • 0 views
  • 07 Oct, 2022
  • 1 location
Safety of SP-420 in the Treatment of Transfusional Iron Overload

This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420

chelators
hysterectomy
packed red blood cells
chelation therapy
iron chelator
  • 0 views
  • 07 Oct, 2022
  • 1 location
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria (STIMULUS-MDS3)

very high risk myelodysplastic syndrome (MDS) who are not suitable for treatment with intensive chemotherapy or a stem-cell transplant (HSCT).

cell transplantation
azacitidine
  • 2 views
  • 21 Oct, 2022
  • 5 locations
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome (ENHANCE)

with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

remission
azacitidine
high risk myelodysplastic syndrome
  • 6 views
  • 23 Oct, 2022
  • 170 locations
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)

, and newly diagnosed with higher-risk myelodysplastic syndrome (MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate

remission
azacitidine
  • 2 views
  • 20 Oct, 2022
  • 48 locations